SG Americas Securities’s Endocyte, Inc. Common Stock ECYT Stock Holding History

SG Americas Securities’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-6,574	Closed	-$117K	–	3498
2018 Q3	$117K	Buy	+6,574	New	+$113K	﹤0.01%	2810
2015 Q4	–	Sell	-15,184	Closed	-$70K	–	3122
2015 Q3	$70K	Buy	+15,184	New	+$79.5K	﹤0.01%	1930
2015 Q1	–	Sell	-22,826	Closed	-$144K	–	3273
2014 Q4	$144K	Buy	+22,826	New	+$139K	﹤0.01%	2671
2013 Q4	–	Sell	-14,437	Closed	-$192K	–	3203
2013 Q3	$192K	Buy	+14,437	New	+$228K	﹤0.01%	2213

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

SG Americas Securities's ECYT Position: Q4 2018 in Review

SG Americas Securities sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 6,574 shares — an estimated $117K sold.

SG Americas Securities first reported a position in ECYT in Q3 2013 and held it in 4 quarters. The position peaked at $192K in Q3 2013. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

SG Americas Securities reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
SG Americas Securities sold 6,574 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $117K.
SG Americas Securities first reported a position in Endocyte, Inc. Common Stock in Q3 2013 and held it in 4 quarters.
SG Americas Securities's Endocyte, Inc. Common Stock position peaked at $192K in Q3 2013.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on SG Americas Securities's 13F filing for Q4 2018, filed 1 Feb 2019.